SRP 1004
Alternative Names: ARO-ATXN2; SRP-1004Latest Information Update: 16 Feb 2025
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Ataxin-2 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Spinocerebellar ataxias
Most Recent Events
- 10 Feb 2025 Arrowhead Pharmaceuticals completes global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programme
- 27 Nov 2024 Arrowhead Pharmaceuticals enters into global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programme
- 26 Nov 2024 Phase-I/II clinical trials in Spinocerebellar ataxias in New Zealand (Intrathecal) (NCT06672445) (EudraCT-2024-514763-25),